Close Menu

NEW YORK — German bioinformatics firm Noscendo has signed an agreement to collaborate with the University Hospital Bonn to characterize antibiotic-resistant pathogens using its Disqver next-generation sequencing-based diagnostic platform, the partners said on Monday.

Noscendo's Disqver is designed to analyze sequenced cell-free DNA from patient blood samples against a database of over 6,000 pathogens in order to detect bacteria, fungi, DNA viruses, and parasites, according to the company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.